Most significantly, we found that patients with osteosarcoma who have high levels of plasma IL-1β at diagnosis are more likely to have metastatic disease at presentation and have a shorter event-free survival (EFS) than those with lower levels of this cytokine. This evidence concerns the gene IL1B and osteosarcoma.